Literature DB >> 26501871

Activation of ETA Receptor by Endothelin-1 Induces Hepatocellular Carcinoma Cell Migration and Invasion via ERK1/2 and AKT Signaling Pathways.

Ning Cong1, Zhongmin Li2, Wenbo Shao1, Jinpeng Li1, Shui Yu3.   

Abstract

Endothelin-1 (ET-1), a member of endothelins family, binds to ETA receptor (ETAR) and ETB receptor to exert its role in multiple cellular processes. Although ET-1 and its receptors has been reported to be overexpressed in many cancers, and overexpression of ET-1 is able to trigger hepatocarcinogenesis in zebrafish, the functions of ET-1 and its receptors in hepatocellular carcinoma (HCC) cell migration and invasion remain unclear. In the present study, we found that ETAR was greatly expressed in HCC cells and HCC tissues. ETAR expression as well as ET-1 expression was associated with vascular invasion and tumor stage in HCC. Activation of ETAR by ET-1 dose-dependently promoted cell migration and invasion of HCC cells, while silencing of ETAR by siRNA or blocking of ETAR by specific inhibitor resulted in significant reduction in ET-1-mediated migration and invasion. Furthermore, ET-1 induced activation of ERK1/2 and AKT and increased MMP-3 production via ETAR. In addition, using inhibitors of ERK1/2 and AKT, we found that ERK1/2 and AKT pathways were both involved in ETAR-mediated migration, invasion, and MMP-3 production. Taken together, our findings suggest that activation of ETAR by ET-1 promotes HCC cell migration and invasion via activating ERK1/2 and AKT signaling pathways and upregulating MMP-3 expression. Thus, ETAR may play an important role in the progress of HCC.

Entities:  

Keywords:  AKT; ERK1/2; ETA receptor; Endothelin-1; Hepatocellular carcinoma; Invasion

Mesh:

Substances:

Year:  2015        PMID: 26501871     DOI: 10.1007/s00232-015-9854-1

Source DB:  PubMed          Journal:  J Membr Biol        ISSN: 0022-2631            Impact factor:   1.843


  25 in total

1.  Endothelin expression and responsiveness in human ovarian carcinoma cell lines.

Authors:  S Moraitis; S P Langdon; W R Miller
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

2.  Exogenous endothelin-1 induces cell migration and matrix metalloproteinase expression in U251 human glioblastoma multiforme.

Authors:  Wen-Tsong Hsieh; Wei-Lan Yeh; Ruo-Yuo Cheng; Chingju Lin; Cheng-Fang Tsai; Bor-Ren Huang; Caren Yu-Ju Wu; Hsiao-Yun Lin; Shiang-Suo Huang; Dah-Yuu Lu
Journal:  J Neurooncol       Date:  2014-04-23       Impact factor: 4.130

Review 3.  Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.

Authors:  Michael A Carducci; Antonio Jimeno
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

4.  Expression profile of endothelin 1 and its receptor endothelin receptor A in papillary thyroid carcinoma and their correlations with clinicopathologic characteristics.

Authors:  Soussan Irani; Ali Salajegheh; Vinod Gopalan; Robert Anthony Smith; Alfred King-Yin Lam
Journal:  Ann Diagn Pathol       Date:  2013-11-15       Impact factor: 2.090

Review 5.  Targeting the endothelin axis in prostate carcinoma.

Authors:  Alvaro Pinto; María Merino; Pilar Zamora; Andrés Redondo; Beatriz Castelo; Enrique Espinosa
Journal:  Tumour Biol       Date:  2011-12-29

6.  Expression of endothelin-1 and endothelin receptor a in canine ovarian tumours.

Authors:  G Borzacchiello; S Mogavero; G Tortorella; G Catone; M Russo
Journal:  Reprod Domest Anim       Date:  2010-12       Impact factor: 2.005

Review 7.  Endothelins and their receptors in cancer: identification of therapeutic targets.

Authors:  Rong Wang; Roderick H Dashwood
Journal:  Pharmacol Res       Date:  2011-01-18       Impact factor: 7.658

Review 8.  New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression.

Authors:  Brigitte Bauvois
Journal:  Biochim Biophys Acta       Date:  2011-10-12

Review 9.  Matrix metalloproteinases in tumor invasion.

Authors:  N Johansson; M Ahonen; V M Kähäri
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

10.  Endothelin-1 enhances cell migration through COX-2 up-regulation in human chondrosarcoma.

Authors:  Min Huan Wu; Li-Mien Chen; His-Hsien Hsu; James A Lin; Yueh-Min Lin; Fuu-Jen Tsai; Chang-Hai Tsai; Chih-Yang Huang; Chih-Hsin Tang
Journal:  Biochim Biophys Acta       Date:  2013-03-21
View more
  7 in total

1.  Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133.

Authors:  Wonhee Hur; Jae Yong Ryu; Hyun Uk Kim; Sung Woo Hong; Eun Byul Lee; Sang Yup Lee; Seung Kew Yoon
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

Review 2.  Emerging Roles of G Protein-Coupled Receptors in Hepatocellular Carcinoma.

Authors:  Wen-Ting Peng; Wu-Yi Sun; Xin-Ran Li; Jia-Chang Sun; Jia-Jia Du; Wei Wei
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

3.  Elucidating essential kinases of endothelin signalling by logic modelling of phosphoproteomics data.

Authors:  Alexander Schäfer; Enio Gjerga; Richard Wd Welford; Imke Renz; Francois Lehembre; Peter Ma Groenen; Julio Saez-Rodriguez; Ruedi Aebersold; Matthias Gstaiger
Journal:  Mol Syst Biol       Date:  2019-08       Impact factor: 11.429

4.  Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor.

Authors:  Chae Young Hwang; Su Jong Yu; Jae-Kyung Won; Sang-Min Park; Jung-Hwan Yoon; Kwang-Hyun Cho; Hyojin Noh; Soobeom Lee; Eun Ju Cho; Jeong-Hoon Lee; Kyung Bun Lee; Yoon Jun Kim; Kyung-Suk Suh
Journal:  Cancer Gene Ther       Date:  2021-08-06       Impact factor: 5.854

5.  Clinicopathological Significance of the ET Axis in Human Oral Squamous Cell Carcinoma.

Authors:  Hiroki Miyazawa; Koroku Kato; Yutaka Kobayashi; Mariko Hirai; Iyo Kimura; Hiroko Kitahara; Natsuyo Noguchi; Hiroyuki Nakamura; Shuichi Kawashiri
Journal:  Pathol Oncol Res       Date:  2018-10-31       Impact factor: 3.201

6.  Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis.

Authors:  Lucy Kappes; Ruba L Amer; Sabine Sommerlatte; Ghada Bashir; Corinna Plattfaut; Frank Gieseler; Timo Gemoll; Hauke Busch; Abeer Altahrawi; Ashraf Al-Sbiei; Shoja M Haneefa; Kholoud Arafat; Lena F Schimke; Nadia El Khawanky; Kai Schulze-Forster; Harald Heidecke; Anja Kerstein-Staehle; Gabriele Marschner; Silke Pitann; Hans D Ochs; Antje Mueller; Samir Attoub; Maria J Fernandez-Cabezudo; Gabriela Riemekasten; Basel K Al-Ramadi; Otavio Cabral-Marques
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

7.  Suppressing ERK Pathway Impairs Glycochenodeoxycholate-Mediated Survival and Drug-Resistance in Hepatocellular Carcinoma Cells.

Authors:  Bingxin Li; Maojun Zhou; Jue Wang; Hongjuan Xu; Manyi Yang
Journal:  Front Oncol       Date:  2021-07-13       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.